Parimifasor

N/A

Report date: 2023/05/01 20:00:20
NME

Base Information

Drug NameParimifasor
Drug Alias NameLYC-30937-Enteric coatedLYC-30937LYC-30937-EC
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionATP synthase modulators
TargetsATP synthase
Therapy Area/IndicationsPsoriasisColitis, Ulcerative
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaCanadaUnited States +[7] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesLycera Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesLycera Corp
Active IndicationsN/A
Inactive IndicationsPsoriasisColitis, Ulcerative

Other Information

ATC CodeN/A
Related LinksN/A